Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：6
|
作者：
Maruyama, Dai [1 ]
Nagai, Hirokazu [2 ]
Fukuhara, Noriko [3 ]
Kitano, Toshiyuki [4 ]
Ishikawa, Takayuki [5 ]
Nishikawa, Tomoaki [6 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[2] Natl Hosp Org Nagoya Med Ctr, Dept Hematol, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan
[5] Kobe City Med Ctr Gen Hosp, Dept Hematol, Kobe, Hyogo, Japan
[6] Janssen Pharmaceut KK, Tokyo, Japan
来源：
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2019年 / 59卷 / 02期
关键词：
covalent BTK inhibitor; ibrutinib; Japanese patients; mantle cell lymphoma; phase II clinical trial;
D O I：
10.3960/jslrt.19006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 100
页数：3
相关论文
共 50 条
  • [21] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
    Jerkeman, Mats
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Christensen, Jacob H.
    Kuitunen, Hanne
    Eskelund, Christian Winther
    Groenbaek, Kirsten
    Niemann, Carsten Utoft
    Geisler, Christian H.
    Kolstad, Arne
    BLOOD, 2020, 136
  • [22] Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma
    Shin, Junghoon
    Lee, Ji Yun
    Lee, Gyeong-Won
    Kim, Won Seog
    Park, Yong
    Do, Young Rok
    Kim, Dae Sik
    Kim, Ki Hwan
    Choi, Yoon Seok
    Byun, Ja Min
    Hong, Junshik
    Kim, Inho
    Yoon, Sung-Soo
    Koh, Youngil
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (06) : E54 - E57
  • [23] Phase II study of enzastaurin in the treatment of relapsed/refractory mantle cell lymphoma.
    Morschhausser, Frank
    Wolf, Martin
    Seymour, John
    Tilly, Herve
    Pfreundschuh, Michael
    Kluin-Nelemans, Hanneke
    Raemaekers, John
    van't Veer, Mars B.
    Milpied, Noel
    Cartron, Guillaume
    Pezzutto, Antonio
    Spencer, Andrew
    Darstein, Christelle
    Thornton, Donald
    Dreyling, Martin
    Reyes, Felix
    BLOOD, 2006, 108 (11) : 694A - 694A
  • [24] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang, Michael L.
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana H.
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreyling, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter
    Spurgeon, Stephen E.
    Li, Lei
    Zhang, Liang
    Newberry, Kate
    Ou, Zhishuo
    Cheng, Nancy
    Fang, Bingliang
    McGreivy, Jesse
    Clow, Fong
    Buggy, Joseph J.
    Chang, Betty Y.
    Beaupre, Darrin M.
    Kunkel, Lori A.
    Blum, Kristie A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516
  • [25] Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
    Cohen, Jonathon B.
    Jegede, Opeyemi
    Portell, Craig A.
    Hamadani, Mehdi
    Diefenbach, Catherine S.
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Mantha, Suparna
    Kahl, Brad S.
    BLOOD, 2022, 140 : 6487 - 6488
  • [26] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Alvarez, Ruben Fernandez
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [27] Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
    Portell, Craig A.
    Wages, Nolan A.
    Kahl, Brad S.
    Budde, Lihua E.
    Chen, Robert W.
    Cohen, Jonathon B.
    Varhegyi, Nikole E.
    Petroni, Gina R.
    Williams, Michael E.
    BLOOD ADVANCES, 2022, 6 (05) : 1490 - 1498
  • [28] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [29] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Fernandez Alvarez, Ruben
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2024, 144 : LBA5 - LBA5
  • [30] Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
    Baggio, Diva
    Wellard, Cameron
    Chung, Eliza
    Talaulikar, Dipti
    Keane, Colm
    Opat, Stephen
    Giri, Pratyush
    Minson, Adrian
    Cheah, Chan Yoon
    Armytage, Tasman
    Lee, Denise
    Chong, Geoffrey
    Johnston, Anna
    Cochrane, Tara
    Waters, Neil
    Hamad, Nada
    Wood, Erica M.
    Hawkes, Eliza A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 621 - 627
12345